SandozSandoz strengthens US biosimilar market with CIMERLI acquisition

2024-03-04
Pharmaceutical Technology
上市批准并购
Sandoz strengthens US biosimilar market with CIMERLI acquisition
Preview
来源: Pharmaceutical Technology
Sandoz’s CIMERLI comes in two concentrations, 6mg/mL and 10mg/mL. Credit: megaflopp / Shutterstock.com.
Sandoz has concluded the acquisition of the US biosimilar CIMERLI from Coherus BioSciences, marking a significant expansion of its ophthalmology and biosimilar expertise in the US market.
The transaction, valued at $170m in upfront cash, encompasses the full CIMERLI business, including a biologics licence application, product inventory, specialised commercial software, ophthalmology sales and field reimbursement talent.
CIMERLI, a US Food and Drug Administration (FDA)-approved biosimilar to the reference product LUCENTIS, is indicated for the treatment of retinal diseases. These can lead to significant vision loss and are among the top ten causes of disability in the country.
The biosimilar, which is an anti–vascular endothelial growth factor therapy, has been shown to help patients with retinal diseases maintain or improve their vision.
The acquisition was agreed by the companies in January 2023.
See Also:BioCorRx files patent for treating diseases and disorders using compound 1
Sandoz strengthens US biosimilar market with CIMERLI acquisition
Preview
来源: Pharmaceutical Technology
Sandoz strengthens US biosimilar market with CIMERLI acquisition
Preview
来源: Pharmaceutical Technology
CIMERLI comes in 6mg/mL and 10mg/mL concentrations and is designed for injection.
Approved by the FDA in August 2022 and launched two months later, CIMERLI met the regulator’s standards of biosimilarities, including safety, efficacy and quality.
It is the first and only FDA-approved biosimilar interchangeable with LUCENTIS for all its indications.
Sandoz North America president Keren Haruvi stated: “Today, we further expand the SandozSandoz biosimilar portfolio while advancing our mission in the US of pioneering patient access to more affordable and much-needed medicines.
“With the addition of CIMERLI to our existing ophthalmology franchise, we can now offer even more treatment options for US patients with vision impairment and loss.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。